GENE SILENCING AT THE DNA LEVEL

Serial Number 88949940
602

Registration Progress

Application Filed
Jun 5, 2020
Under Examination
Approved for Publication
Published for Opposition
Registered

Re-Apply for This Trademark

This trademark is no longer active. You may be able to file a new application for the same or similar mark.
Mark: GENE SILENCING AT THE DNA LEVEL
Previous Owner: Oncogenuity Inc.
Classes: 042

Trademark Image

GENE SILENCING AT THE DNA LEVEL

Basic Information

Serial Number
88949940
Filing Date
June 5, 2020
Abandonment Date
October 6, 2021
Drawing Code
4000

Status Summary

Current Status
Inactive
Status Code
602
Status Date
Oct 18, 2021
Classes
042

Rights Holder

Oncogenuity Inc.

03
Address
2 Gansevoort Street 9th Floor
New York, NY 10014

Ownership History

Oncogenuity Inc.

Original Applicant
03
New York, NY

Legal Representation

Attorney
Devon E. White

USPTO Deadlines

No Upcoming Deadlines

No upcoming deadlines found for this trademark.

Application History

14 events
Date Code Type Description Documents
Oct 18, 2021 MAB2 E ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND Loading...
Oct 18, 2021 ABN2 O ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE Loading...
Apr 5, 2021 GNFN O NOTIFICATION OF FINAL REFUSAL EMAILED Loading...
Apr 5, 2021 GNFR O FINAL REFUSAL E-MAILED Loading...
Apr 5, 2021 CNFR R FINAL REFUSAL WRITTEN Loading...
Mar 16, 2021 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Mar 15, 2021 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Mar 15, 2021 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Sep 16, 2020 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Sep 16, 2020 GNRT F NON-FINAL ACTION E-MAILED Loading...
Sep 16, 2020 CNRT R NON-FINAL ACTION WRITTEN Loading...
Sep 9, 2020 DOCK D ASSIGNED TO EXAMINER Loading...
Jun 26, 2020 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Jun 9, 2020 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 042
Pharmaceutical product development services; Pharmaceutical product evaluation services; Pharmaceutical research and development; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Research and development of pharmaceuticals for the treatment of cancer and oncological conditions; Research and development of vaccines and medicines; Technical research in the field of pharmaceutical studies; Development of platform technology, namely, developing a cancer immunotherapy computer platform for manufacturing therapeutics; Consulting services for others in the field of design, planning, and implementation of clinical trials; IT platform as Service (PaaS) featuring computer software platforms for cancer diagnosis and analysis of cancer symptoms and cancer treatment, in the medical field; electronic data storage; Providing a bioinformatics platform as a service (PAAS) featuring computer software platforms for sequence data analysis in the field of manufacturing therapeutics; Medical and scientific research information in the field of cell therapy; Scientific research and analysis for medical purposes in the field of cancer, oncology and clinical trials
First Use Anywhere: 0
First Use in Commerce: 0

Classification

International Classes
042